NCT05524610Recruiting
Development and Evaluation of a Screening Approach for Sexual Dysfunction in AYA Patients With and Surviving Childhood Cancer
Stakeholder-Engaged Development and Evaluation of a Screening Approach for Sexual Dysfunction in Adolescent and Young Adult Patients With and Surviving Childhood Cancer
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
Prior research determined adolescent and young adult-aged childhood cancer survivor (AYA-CCS) and medical provider acceptability of the SexFS Brief in a controlled research setting. Development of an acceptable, effective, and feasible screening approach will result in improved recognition of SD in AYA patients with and surviving childhood cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 205 (estimated)
- First submitted
- 25 Aug 2022
- Start date
- 14 Feb 2023
- Primary completion date
- 30 Mar 2027
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Childhood cancers
- NCT number
- NCT05524610
What you commit to
- Study type: Interventional
- Planned participants: 205
- From 14 Feb 2023 to the primary completion date, 30 Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who did not receive cancer-directed therapy
Other
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Unable to read and speak English
- Insufficient cognitive functioning to complete study measures, as determined by patient's
- Participation in intervention development
- Patient is at end of life or on hospice, as determined by primary oncologist
- Patients who did not undergo sexual function screening within 1 month of being due will be excluded from implementation outcomes measurement
- Patient is at end of life or on hospice, as determined by primary oncologist
Who the study is looking for
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision to sign and date the consent form.
- Stated willingness to comply with all study procedures and be available for the duration of the study.
- Be aged 15-24 years old at the time of enrollment
- Patients with or surviving of cancer (must be found in the International Classification of Diseases for Oncology (ICD-O) and have a behavior code ≥2)
- Must have received cancer-directed therapy with at least one of the following:
- Chemotherapy: any anticancer drug to treat the cancer diagnosis including immunotherapy
- Radiotherapy: any radiotherapy to treat the cancer diagnosis
- Surgery: any surgery to remove cancer including partial or total resections. Biopsies are not considered surgery.
- Cancer must have been diagnosed before the age of 18 years
- Patient must have an appointment at one of four clinical sites: CHCO HOPE Survivorship Program, CHCO Oncology Clinic, CHCO Neuro-Oncology Clinic, Seattle Children's Hospital Survivorship Program
Age in the registry: 15 years to 24 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Hospital Coordinator of this site? Confirm its status | Aurora | United States | Recruiting |
| Childrens Hospital Colorado Coordinator of this site? Confirm its status | Aurora | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.